Although we are in a pandemic, patient needs continue unabated and often are made more dire by the intense focus on COVID that investments, regulatory bodies and government are taking. There are important life-saving technologies, still in various stages of development, that companies are attempting to guide through a process fraught with barriers in the best of times and now struggling against the immediacy of COVID. Our panelists will share their insights on staying the course, getting funding, regulatory approval and a product to market when the product is not COVID related.
Alyssa Schmidt, associate director, global regulatory consulting, Syneos Health
Tony Voiers, chief executive officer, Advanced Chemotherapy Technologies